Announcements
- Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
- Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
- Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
More ▼
Key statistics
On Tuesday, Pliant Therapeutics Inc (9PT:DEU) closed at 11.90, 25.93% above the 52 week low of 9.45 set on Jul 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.90 |
Low | 11.20 |
Bid | 11.80 |
Offer | 11.90 |
Previous close | 11.50 |
Average volume | 349.30 |
---|---|
Shares outstanding | 60.33m |
Free float | 58.54m |
P/E (TTM) | -- |
Market cap | 755.88m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of Jul 23 2024.
More ▼